Retatrutide is a novel investigational peptide that functions as a multi-receptor agonist, targeting GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. It is being researched for its potential effects on metabolic regulation, including blood glucose control and weight management.

• Mechanism of Action: By activating these three receptors, Retatrutide enhances insulin secretion, suppresses appetite, increases energy expenditure, and supports glucose regulation. Its multi-receptor approach is designed to offer improved metabolic outcomes compared to single-receptor agonists.

This compound is intended exclusively for research purposes and is not approved for human consumption. It must be handled by qualified professionals in controlled laboratory settings.